good morning, everyone. Thanks, and Andrew,
following discussed then year have our progress onetime be launch plans the to bring morning treatments deeper commercial this into here first ZYNTEGLO a to exciting made the ago, It's Almost we patients. to since our we approval. to dive
or pillars We great are continue gene QTC forging to vivo patient and reimbursement. demand, treatment access center the quarter, the commercial qualified across U.S. including model for make this our and onboarding launch, and of key the therapy progress ex we in
to how groundwork for dynamic is the insight accelerate additional laid we some growth into and give to commercial that want ZYNTEGLO for quarter-over-quarter. projected the launch foundation the have We has built
their we ZYNTEGLO treating by these five every we September. of those which X fact, patient In the second, most August or their started a QTCs of XXXX, fourth with one are launch end centers we even Wave said Today, QTCs, would of in have accomplished and third patient.
started patient were in on five last activated Wave to of Wave have track the year, rest excited or coming that to by QTCs Our start of QTCs our report the a we next with patient are months. and X end the XX% X a
in recently Wave We and These are and the centers onboarded more enrollment have identification, currently process scheduling. activating patient QTCs. our been of are X
activation, We of they lovo-cel. are trust incredibly the to our led are down our identifying which process. for building and They are the interest become better, weeks to more This time all gaining patients are QTC is have valuable acceleration to network, and they our for an with with understanding process familiar expected two bring QTC reimbursement for experience. ZYNTEGLO of months activation
time. on patients. to ultimately XXXX more remain XX the year commercial we therapy and is progressing scale by launch exactly QTC this would bluebird expand launch and to over would end linear to how to The gradual vivo ex between continuing ZYNTEGLO the build network we into of expect continue to reach gene XX trajectory track and momentum and with And will likely an
after soon head flash individuals further low ready we the their experience are anticipated these capitalizing if start with leverage able will next to on be our centers year, early XX-month and administering treat potential to cell ZYNTEGLO cell on competition. from sickle be disease to to Now approval, forward the
part a as reminder, a Delivering therapy gene and that families. is therapy and consistent key their a integral and supply is And of transplant chain. patients is providers the part the is essential element for center reliable key for an physicians, ex a vivo delivering and manufacturing of process gene of
and these have the from our with patient through entire partnership We QTC all built process commitment a throughout onboarding infusion. to way reputation the centers transparency strong through
and is the their average post-cell of on then ZYNTEGLO, hospital. driven and XX release to deliver XX days the back takes schedules. by test, infusion For patients, manufacture, primarily collection, to ZYNTEGLO physicians to it therapy The
And translate infusions largely this Andrew phase lovo-cel is way. the our as process another focus as of for where on infusion. of the This starts currently, and and vivo upon expectation, example is patient earlier, yet this process lead other ex that be at noted bluebird to revenue will in for therapies to gene continue indicator we revenue treatment the And leading the launch, completed. the recognizes with are as bluebird same space and starts
lovo-cel sickle disease. Transitioning to for cell
impact launch the want about preparations everyone seen in I the Before therapy opportunity, commercial the of remind our trials. transformative to and clinical of talk I
robust most for the reflects with the data disease. data across clinical cell any Our follow-up therapy program longest sickle gene available
and August months, with cell were of data vaso-occlusive adverse disease a showed resolution XX lovo-cel or sickle attributed More across the of patients package XX from entire includes of of treated specifically, underlying data conditioning XX% patients with From from events BLA median XXXX data months set, our severe to events program. XX our efficacy follow-up XX complete safety the busulfan. and we through majority
the the these we been cell continue has devastating to severity early through to that well for disease package, review for Preparations a patients ignored this The and its historically of need December underappreciated. underway Sickle great. unmet 'XX year. look is are XX the in FDA of approved. our PDUFA forward on with is launch work if commercial our We and
meaningful is with years transplanters than options in giving more demonstrated lovo-cel seven significant confidence performed treaters, market for with consistently patients, have patients, ahead. of great We has and the research treatment us sickle which opportunity that cell
left-hand Starting and seen and on their clearly would gene patients have the eagerness side we slide, therapy doctor. XX% recommended than found strong to patient there gene more we have therapy, of of consistently by for in gene that grow. if therapy is continues Demand consider for the excitement
to Moving the middle.
the patients are research to greatest modality providers The of and show simply that does another. partial misperceptions One over not is one it.
than not make shows on long-term based of In more decision but on on a follow-up based treatment fact, modality. and that research efficacy will market based patients XX%
which the finally, lovo-cel and a they after respondents were were seen direct of the XX% available have therapy disease. market reviewed This and was capture market established This competitor. product point over prefer then lovo-cel, most a gene a share years, the is a robust asked has clinical on one cell profiles through both differentiating research any would both between market. and And our longest sickle for to XX% we for profile safety key which against
these key coupled great All earlier making between our demand, the that patient reimbursement, with the talked ZYNTEGLO market readiness of community. cell QTC of for we're our decade-long bluebird launch, access our And and research this pillars and pillars on finalizing and already lovo-cel. is sickle network a progress I including and and launch patient partnership pleased about I'm
evidenced clear to continue with will patient I the broaden and around by we demand about therapy. and We just discussed, gene education physician are community patient excited the as research to the partner
more become QTC and to momentum. gaining Our network and experience is growing continues efficient,
feedback demonstration for therapy finally, on value about private patients. on the payers to lead payers with value access positive high on and our and from working for And payment models, in we're innovative unmet gene way our critical to continues approach. need government target bluebird excited continued on and medical and outcomes-based is clinical
a confident and are foundation and We to in laying many come. we're therapies, confident difference are patients team, are today making our and we in in the confident in of more our for the we our strategy, lives
Andrew. to Now back
